Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.72 |
| ▸ | CDK4 | P11802 | 13/20 | 0.72 |
| ▸ | PLK1 | P53350 | 2/20 | 0.72 |
| ▸ | AURKA | O14965 | 6/20 | 0.70 |
| ▸ | CDK9 | P50750 | 5/20 | 0.70 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.70 |
| ▸ | CDK1 | P06493 | 4/20 | 0.70 |
| ▸ | CDK7 | P50613 | 4/20 | 0.70 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2073844 | 0.89 | CDK2 (0.72) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL6367646 | 0.89 | CDK2 (0.73) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL4159897 | 0.85 | CDK2 (0.64) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL4160082 | 0.84 | CDK2 (0.65) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL2289103 | 0.84 | CDK2 (1.00) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL12589637 | 0.84 | CDK2 (0.82) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL6157713 | 0.82 | CDK2 (0.74) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL2076580 | 0.82 | CDK2 (0.74) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL6157812 | 0.82 | CDK2 (0.79) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL6157084 | 0.82 | CDK2 (1.00) | CDK2CDK4PLK1AURKACDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100500663-C | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds | CYCLACEL LTD (GB) | 2009-06-17 | — | — | CN | claimed |
| EP-1430051-B1 | N-(4-(4-METHYLTHIAZOL-5-YL)PYRIMIDIN-2-YL)-N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS | CYCLACEL LTD (GB) | 2006-12-27 | — | — | EP | claimed |
| US-20060199830-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2006-09-07 | — | — | US | claimed |
| US-20050288307-A1 | Anti-viral compounds | CYCLACEL LIMITED (GB) | 2005-12-29 | — | — | US | claimed |
| EP-1581231-A1 | ANTI-VIRAL COMPOUNDS | Cyclacel Limited (GB) | 2005-10-05 | — | — | EP | claimed |
| CN-1617870-A | N- (4- (4-methylthiazol-5-yl) pyrimidin-2-yl) -N-anilines as antiproliferative compounds | CYCLACEL LTD (GB) | 2005-05-18 | — | — | CN | claimed |
| US-20040259894-A1 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2004-12-23 | — | — | US | claimed |
| EP-1430051-A1 | N-(4-(4-METHYLTHIAZOL-5-YL)PYRIMIDIN-2-YL)-N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS | Cyclacel Limited (GB) | 2004-06-23 | — | — | EP | claimed |
| WO-2004043467-A1 | ANTI-VIRAL COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | claimed |
| WO-2003029248-A1 | N-(4-(4-METHYLTHIAZOL-5-YL) PYRIMIDIN-2-YL) -N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS | CYCLACEL LIMITED (GB) | 2003-04-10 | — | — | WO | claimed |
| CN-100500663-C | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds | CYCLACEL LTD (GB) | 2009-06-17 | — | — | CN | disclosed |
| US-7427627-B2 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-09-23 | — | — | US | disclosed |
| US-7427627-B2 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-09-23 | — | — | US | disclosed |
| US-7388015-B2 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-06-17 | — | — | US | disclosed |
| EP-1760082-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as anti-proliferative compounds | Cyclacel Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| CN-1617870-A | N- (4- (4-methylthiazol-5-yl) pyrimidin-2-yl) -N-anilines as antiproliferative compounds | CYCLACEL LTD (GB) | 2005-05-18 | — | — | CN | disclosed |
| US-20040259894-A1 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2004-12-23 | — | — | US | disclosed |
| EP-1430051-A1 | N-(4-(4-METHYLTHIAZOL-5-YL)PYRIMIDIN-2-YL)-N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS | Cyclacel Limited (GB) | 2004-06-23 | — | — | EP | disclosed |
| WO-2004043467-A1 | ANTI-VIRAL COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003029248-A1 | N-(4-(4-METHYLTHIAZOL-5-YL) PYRIMIDIN-2-YL) -N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS | CYCLACEL LIMITED (GB) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259894-A1 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CDK4, CDK2, CDKL4 | CDK2 2/4885CDK4 1/4885PLK1 53/4885 |
| US-20060199830-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CDK4, CDK2, CCNI | CDK2 2/4885CDK4 1/4885PLK1 54/4885 |
| US-20050288307-A1 | Anti-viral compounds | MAVS, HAVCR2, EIF2AK2 | CDK2 205/4885CDK4 477/4885PLK1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.